SEC Tracker
Get the app

Angiotech Pharmaceuticals

Angiotech Pharmaceuticals Q2 FY12: revenue $61.3M; diluted EPS −$0.23

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract
Exhibit 10.2
Material contract

Key figures from this report

These are the numbers Angiotech Pharmaceuticals reported for Q2 FY12, the quarter ended Jun 30, 2012, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$61.3MNo year-earlier figure tagged10-Q/A income statement, on EDGAR
  2. Diluted EPS−$0.23No year-earlier figure tagged10-Q/A income statement, on EDGAR
  3. Cash and cash equivalents$58.0MNo year-earlier figure tagged10-Q/A balance sheet, on EDGAR

View on EDGAR

Open in the app

Get an email when Angiotech Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (3841) and public float not reported.

  1. Acutus Medical AFIB
  2. ALR Technologies SG ALRTF
  3. Baird Medical Investment Holdings BDMD
  4. Brain Scientific BRSF
  5. Brainsway BWAY

Data on this page was fetched . The filing on SEC.gov is the record.